Latest period
$55.1B
YoY change
+22.6%
5Y CAGR
+90.2%
Peak year (FY2025)
$54.9B
Latest annual
$54.9B
Total Liabilities history chart for Novo Nordisk (NVO) from 2016 to 2025
Latest: $54.9B
Total Liabilities growth chart for Novo Nordisk (NVO) from 2016 to 2025
Latest: +22.6%
Total Liabilities history table for Novo Nordisk (NVO) from 2003 to 2025
| FY2025 | $54.9B | +22.6% | +$10.1B | ||
| FY2024 | $44.7B | +45.4% | +$14B | ||
| FY2023 | $30.8B | +35.5% | +$8.07B | ||
| FY2022 | $22.7B | +20.0% | +$3.78B | ||
| FY2021 | $18.9B | +759.7% | +$16.7B | ||
| FY2020 | $2.2B | +43.6% | +$669M | ||
| FY2019 | $1.53B | -83.1% | -$7.52B | ||
| FY2018 | $9.05B | +6.9% | +$582M | ||
| FY2017 | $8.47B | +14.5% | +$1.07B | ||
| FY2016 | $7.4B | +13.3% | +$867M | ||
| FY2015 | $6.53B | +9.3% | +$554M | ||
| FY2014 | $5.98B | +16.4% | +$843M | ||
| FY2013 | $5.13B | +15.9% | +$704M | ||
| FY2012 | $4.43B | -6.8% | -$323M | ||
| FY2011 | $4.75B | +8.3% | +$364M | ||
| FY2010 | $4.39B | +19.9% | +$729M | ||
| FY2009 | $3.66B | +10.3% | +$342M | ||
| FY2008 | $3.32B | +8.8% | +$268M | ||
| FY2007 | $3.05B | +18.3% | +$471M | ||
| FY2006 | $2.58B | +13.5% | +$307M | ||
| FY2005 | $2.27B | +13.1% | +$263M | ||
| FY2004 | $2.01B | +29.2% | +$453M | ||
| FY2003 | $1.56B | — | — | ||
| FY2002 | — | — | — | ||
| FY2001 | — | — | — | ||
| FY2000 | — | — | — | ||
| FY1999 | — | — | — | ||
| FY1998 | — | — | — | ||
| FY1997 | — | — | — | ||
| FY1996 | — | — | — | ||
| FY1995 | — | — | — | ||
| FY1994 | — | — | — | ||
| FY1993 | — | — | — | ||
| FY1992 | — | — | — | ||
| FY1991 | — | — | — | ||
| FY1990 | — | — | — | ||
| FY1989 | — | — | — | ||
| FY1988 | — | — | — | ||
| FY1987 | — | — | — | ||
| FY1986 | — | — | — | ||
| FY1985 | — | — | — |
- FY2025$54.9B+22.6%
- FY2024$44.7B+45.4%
- FY2023$30.8B+35.5%
- FY2022$22.7B+20.0%
- FY2021$18.9B+759.7%
- FY2020$2.2B+43.6%
- FY2019$1.53B-83.1%
- FY2018$9.05B+6.9%
- FY2017$8.47B+14.5%
- FY2016$7.4B+13.3%
- FY2015$6.53B+9.3%
- FY2014$5.98B+16.4%
- FY2013$5.13B+15.9%
- FY2012$4.43B-6.8%
- FY2011$4.75B+8.3%
- FY2010$4.39B+19.9%
- FY2009$3.66B+10.3%
- FY2008$3.32B+8.8%
- FY2007$3.05B+18.3%
- FY2006$2.58B+13.5%
- FY2005$2.27B+13.1%
- FY2004$2.01B+29.2%
- FY2003$1.56B—
- FY2002——
- FY2001——
- FY2000——
- FY1999——
- FY1998——
- FY1997——
- FY1996——
- FY1995——
- FY1994——
- FY1993——
- FY1992——
- FY1991——
- FY1990——
- FY1989——
- FY1988——
- FY1987——
- FY1986——
- FY1985——
Total Liabilities values are taken from Novo Nordisk's reported balance sheets (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About Total Liabilities at Novo Nordisk (NVO)
According to Novo Nordisk's latest reported financial statements, the company's latest reported total liabilities is $55.1B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual total liabilities for Novo Nordisk (NVO) came in at 349B DKK – grew 8.2% year-over-year.
Novo Nordisk total liabilities compound annual growth for the 2020–2025 (5 years) window is +91.9%, with mixed annual results across the window.
349B DKK stands as the all-time-high annual total liabilities, posted in 2025, against a low of 2.45B DKK during 1985.
Novo Nordisk Total Liabilities by Year
Novo Nordisk Total Liabilities 2025: $54.9B
2025's total liabilities for Novo Nordisk came in at 349B DKK ($54.9B), grew 8.2% from 2024. This figure represents the highest annual value in the available history.
Novo Nordisk Total Liabilities 2024: $44.7B
Novo Nordisk posted total liabilities of 322B DKK ($44.7B) in 2024, surged 55.0% from 2023.
Novo Nordisk Total Liabilities 2023: $30.8B
In 2023, Novo Nordisk reported total liabilities of 208B DKK ($30.8B), surged 31.8% from 2022.
Novo Nordisk Total Liabilities 2022: $22.7B
Novo Nordisk total liabilities in 2022 was 158B DKK ($22.7B), grew 27.5% from 2021.
Novo Nordisk Total Liabilities 2021: $18.9B
Novo Nordisk total liabilities in 2021 was 124B DKK ($18.9B).
See more financial history for Novo Nordisk (NVO).
Sector peers by Total Liabilities
Healthcare peers of Novo Nordisk (NVO), ranked by their latest total liabilities
| $208B | |
| $137B | |
| $118B | |
| $85.9B | |
| $84.2B | |
| $81.9B | |
| $56.8B | |
| $33.9B |
- $137B
- $85.9B
- $84.2B
- $81.9B
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.23% TTM
- Dividend Profile3.49% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History5 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.